Orphazyme withdraws marketing application ahead of final vote

Biotech company Orphazyme has decided to withdraw its European marketing authorization application for its drug hope, arimoclomol, a potential treatment for Niemann-Pick type C (NPC), a company press release reports.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Orphazyme predicts EU rejection after meeting with CHMP
For subscribers
Orphazyme files for delisting in US
For subscribers